Does Rallies show 13F holders for ADIL?

Yes. Rallies tracks hedge fund and 13F ownership data for ADIL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ADIL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ADIL. It does not provide personalized investment advice.

ADIL (Adial Pharmaceuticals, Inc) Stock Analysis - Hedge Fund Holdings

Adial Pharmaceuticals, Inc (ADIL) is a publicly traded Healthcare sector company. As of May 21, 2026, ADIL trades at $2.34 with a market cap of $3.45M and a P/E ratio of -0.19. ADIL moved +14.08% today. Year to date, ADIL is -63.15%; over the trailing twelve months it is -87.06%. Its 52-week range spans $1.31 to $32.50. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ADIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ADIL stock?

Hedge funds tracked by Rallies that own ADIL include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Adial Pharmaceuticals, Inc.

ADIL Key Metrics

Key financial metrics for ADIL
Metric	Value
Price	$2.34
Market Cap	$3.45M
P/E Ratio	-0.19
EPS	$-11.93
Dividend Yield	0.00%
52-Week High	$32.50
52-Week Low	$1.31
Volume	686
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-7.98M
Gross Margin	0.00%

Top Hedge Funds Holding ADIL

Citadel Advisors holds 54.51K shares of ADIL, changed +63.84% as of Dec 31, 2024.
Renaissance Technologies holds 47.61K shares of ADIL, changed +38.63% as of Dec 31, 2024.

Latest ADIL News

FDA Flexibility Could Cut AD04 Costs; Company Holds $4.6M, Eyes Europe — May 11, 2026
Adial Pharmaceuticals Files U.S. Patent for AD04, Potential Protection Through 2045 — Apr 29, 2026
Adial Completes AD04 Demonstration Batch Meeting All Spec Targets for Phase 3 — Apr 22, 2026
Bill Expands AUD Research for Veterans, Elevates Adial’s AD04 Potential — Mar 24, 2026
Adial Ends 2025 with $5.9M Cash, R&D Down 19%, AD04 Phase 3 Ready — Mar 6, 2026

Recent ADIL Insider Trades

Schuyler Kevin bought 700 (~$1.92K) on Sep 29, 2023.
Newman James W. Jr. bought 10.00K (~$26.60K) on Dec 30, 2021.
Newman James W. Jr. bought 5.00K (~$13.60K) on Dec 30, 2021.

ADIL Analyst Consensus

1 analysts cover ADIL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about ADIL

Who owns ADIL stock?: Hedge funds tracked by Rallies that own ADIL include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Adial Pharmaceuticals, Inc.
Does Rallies show 13F holders for ADIL?: Yes. Rallies tracks hedge fund and 13F ownership data for ADIL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ADIL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ADIL. It does not provide personalized investment advice.